Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
Tuesday, July 21, 2026 1 min read
Key Takeaway: Phio Pharmaceuticals has appointed Dr. R. Todd Plott to its Board of Directors. Dr. Plott brings a wealth of experience in patient care and dermatologic research, which may enhance the company's strategic direction. This move is expected to bolster Phio's efforts in developing therapeutics using its INTASYL® gene silencing technology.
Price reaction · baseline $1.08 (2026-07-20 close) · hit pre-market · clean, no other PHIO news in the window
day 0 close · peak
+4.6%
Market Sentiment Analysis
POSITIVE FACTORS
Dr. R. Todd Plott brings extensive experience in patient care.
His background in dermatologic research enhances the board's expertise.
The appointment may strengthen Phio's strategic direction.
Full Press Release Details
Brings extensive experience in patient care, dermatologic research and commercialization King of Prussia, Pennsylvania–(Newsfile Corp. – July 21, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been […]
The post Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors appeared first on Phio Pharmaceuticals .
Frequently Asked Questions
Who is Dr. R. Todd Plott?
Dr. R. Todd Plott is a medical doctor with extensive experience in patient care and dermatologic research.
What is Phio Pharmaceuticals known for?
Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using gene silencing technology.
What technology does Phio use?
Phio utilizes its proprietary INTASYL® gene silencing technology to develop cancer therapeutics.
What impact may Dr. Plott's appointment have?
Dr. Plott's appointment may strengthen Phio's strategic direction and enhance its board expertise.